Mechanism of action of 6, 7, 8, 9, 10, 12-hexahydro-azepino-[2, 1-b] quinazolin-12-one-(RLX)--a novel bronchodilator.
Indian J Physiol Pharmacol
;
2000 Jan; 44(1): 75-81
Artigo
em Inglês
| IMSEAR
| ID: sea-108959
ABSTRACT
The present study presents a mode of action profile of RLX (6, 7, 8, 9, 10, 12-hexahydro-azepino-[2, 1-b]-quinazoline-12-one) a bronchodilator obtained by the chemical modification in the molecule of alkaloid vasicine (Ex Adhatoda vesica). The effect of RLX (p.o.) was observed on (a) mast cell degranulation, (b) release of histamine and prostaglandin E (PGE), (c) 45Ca uptake and (d) activities of cAMP phosphodiesterase (PDEase) and lipoxygenase enzymes in mesenteries/peritoneal mast cells/lung tissue homogenates in rats under systemic anaphylaxis. RLX (10 and 20 mg/kg) inhibited antigen-induced mast cell degranulation and released of histamine from target tissues. An increased outflow of PGE (lungs) and an inhibited 45Ca uptake (peritoneal mast cells) were noted. Lung PDEase and lipoxygenase activities were decreased. These results suggested that RLX could be acting like disodium cromoglycate and aminophyline with additional attributes its oral efficacy and long duration of action.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Quinazolinas
/
Ratos
/
Broncodilatadores
/
Masculino
/
Degranulação Celular
/
Cálcio
/
Eletroforese em Gel de Poliacrilamida
/
Liberação de Histamina
/
Cavalos
/
Hipersensibilidade
Idioma:
Inglês
Revista:
Indian J Physiol Pharmacol
Ano de publicação:
2000
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS